Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion type Assertion NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_head.
- NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion description "[The use of FASN inhibitors has been limited until now by anorexia and weight loss, which is associated with the stimulation of fatty acid oxidation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_provenance.
- NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion evidence source_evidence_literature NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_provenance.
- NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion SIO_000772 19189648 NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_provenance.
- NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion wasDerivedFrom befree-20150227 NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_provenance.
- NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_assertion wasGeneratedBy ECO_0000203 NP394893.RAdO9-qgv9JwmeXIdbiIn7kRwGG48oxd1Rma1f-4NYHCY130_provenance.